A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 55, Issue 12, Pages 2761-2768
Publisher
Informa UK Limited
Online
2014-03-29
DOI
10.3109/10428194.2014.907891
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation and critical assessment of putative MCL-1 inhibitors
- (2013) S Varadarajan et al. CELL DEATH AND DIFFERENTIATION
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database
- (2012) A. S. LaCasce et al. BLOOD
- Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
- (2012) R W Rooswinkel et al. Cell Death & Disease
- Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas
- (2011) Elizabeth A. Brem et al. BRITISH JOURNAL OF HAEMATOLOGY
- ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1lowProfile and Synergizes with Other Antineoplastic Agents
- (2011) Cyrille Touzeau et al. CLINICAL CANCER RESEARCH
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
- (2010) P. Perez-Galan et al. BLOOD
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis
- (2010) Sameer A. Parikh et al. Clinical Lymphoma Myeloma & Leukemia
- Mantle cell lymphoma: The promise of new treatment options
- (2010) Andre Goy et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
- (2008) L. Paoluzzi et al. BLOOD
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
- (2008) S. M. O'Brien et al. BLOOD
- The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
- (2008) L. Paoluzzi et al. BLOOD
- Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
- (2008) Yuhong Zhou et al. CANCER
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
- (2008) A. D. Schimmer et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started